Impact of SGLT-2 Inhibitors on Biomarkers of Heart Failure
Abstract
Type 2 diabetes mellitus affects nearly 7% of the world's population and is a significant contributor to the development of cardiovascular disease and heart failure. Historically, the pharmacologic therapy of cardiovascular disease has centered around blood pressure control, insulin and cholesterol management, the inhibition of the renin-angiotensin system, and catecholamine blockade. Recent evidence suggests that sodium-glucose cotransporter 2 (SGLT-2) inhibitors provide significant cardiovascular protection to patients with and without diabetes. The use of SGLT-2 inhibitors is associated with significant changes to serum biomarkers of cardiac function. In this narrative review, we summarize how biomarkers reflect physiologic aspects of cardiovascular function and how these are affected by the use of SGLT-2 inhibitors.
Read the paper
Related studies
- Risk Factors for Coronavirus Disease 2019 (COVID-19) Death in a Population Cohort Study from the Western Cape Province, South Africa
- Global and regional estimates of genital human papillomavirus prevalence among men: a systematic review and meta-analysis
- A methodology for assessing deployment trauma and its consequences in OEF/OIF/OND veterans: The TRACTS longitudinal prospective cohort study
- Post‑COVID‑19 Syndrome in Outpatients: a Cohort Study
- Factors Influencing Primary and Secondary Implant Stability—A Retrospective Cohort Study with 582 Implants in 272 Patients
- Electroacupuncture for Painful Diabetic Peripheral Neuropathy: A Multicenter, Randomized, Assessor-Blinded, Controlled Trial
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.